Malignant Salivary Gland Neoplasm

Diseases /

Malignant Salivary Gland Neoplasm

Back to Diseases List

Associated Genetic Biomarkers

ABL1
ABL1 Amplification
ABL1 Fusion
ABL1 Mutation
AR Expression
AR Positive
BRAF
BRAF Amplification
BRAF Mutation
DDR2
DDR2 Amplification
DDR2 Mutation
EGFR
EGFR Amplification
EGFR Mutation
EPHA2
EPHA2 Amplification
EPHA2 Mutation
ERBB2
ERBB2 Amplification

ERBB2 Mutation
ERBB4
ERBB4 Amplification
ERBB4 Loss
ERBB4 Mutation
FGFR1
FGFR1 Amplification
FGFR1 Fusion
FGFR1 Mutation
FGFR2

FGFR2 Amplification
FGFR2 Fusion
FGFR2 Mutation
FLT1
FLT1 Amplification
FLT1 Mutation
FLT4
FLT4 Amplification
FLT4 Mutation
FRK

FRK Mutation
HER2 Overexpression
HER2 Positive
KDR
KDR Amplification
KDR Mutation
KIT
KIT Amplification
KIT Fusion
KIT Mutation

MAPK11
MAPK11 Amplification
MAPK11 Mutation
NTRK1
NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3
NTRK3 Fusion
PDGFRA

PDGFRA Amplification
PDGFRA Fusion
PDGFRA Mutation
PDGFRB
PDGFRB Amplification
PDGFRB Fusion
PDGFRB Mutation
RAF1
RAF1 Amplification
RAF1 Mutation

RET
RET Amplification
RET Fusion
RET Mutation
TEK
TEK Mutation
TRNAK2
TRNAK2 Mutation
VEGFA
VEGFA Amplification

VEGFB
VEGFB Amplification
VEGFC
VEGFC Amplification

Overview

NCI Definition: A carcinoma that arises from the major or minor salivary glands. Representative examples include carcinoma ex pleomorphic adenoma, adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma. [1]

Biomarker-Directed Therapies

View Therapies for Malignant Salivary Gland Neoplasm

Of the biomarker-directed therapies for malignant salivary gland neoplasm, 0 are FDA-approved in at least one setting and 5 have NCCN guidelines in at least one setting [3].

Ado-Trastuzumab Emtansine +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

HER2 Positive (General)

Clinical Setting(s): Metastatic (NCCN)

Note: NCCN recommended for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic).

Biomarker Criteria: Sample must match one or more of the following: HER2 Positive (General)	Clinical Setting(s): Metastatic (NCCN)
	Note: NCCN recommended for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic).

Bicalutamide +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

AR Positive

Clinical Setting(s): Metastatic (NCCN)

Note: A significant number of advanced salivary gland tumors are AR+, and NCCN recommends that these patients may receive androgen receptor therapy.

Biomarker Criteria: Sample must match one or more of the following: AR Positive	Clinical Setting(s): Metastatic (NCCN)
	Note: A significant number of advanced salivary gland tumors are AR+, and NCCN recommends that these patients may receive androgen receptor therapy.

Leuprolide +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

AR Positive

Clinical Setting(s): Metastatic (NCCN)

Note: A significant number of advanced salivary gland tumors are AR+, and NCCN recommends that these patients may receive androgen receptor therapy.

Biomarker Criteria: Sample must match one or more of the following: AR Positive	Clinical Setting(s): Metastatic (NCCN)
	Note: A significant number of advanced salivary gland tumors are AR+, and NCCN recommends that these patients may receive androgen receptor therapy.

Trastuzumab +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

HER2 Positive (General)

Clinical Setting(s): Metastatic (NCCN)

Note: NCCN recommended as a single agent or in combination with docetaxel for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic).

Biomarker Criteria: Sample must match one or more of the following: HER2 Positive (General)	Clinical Setting(s): Metastatic (NCCN)
	Note: NCCN recommended as a single agent or in combination with docetaxel for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic).

Pertuzumab + Trastuzumab +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

HER2 Positive (General)

Clinical Setting(s): Metastatic (NCCN)

Note: NCCN recommended for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic).

Biomarker Criteria: Sample must match one or more of the following: HER2 Positive (General)	Clinical Setting(s): Metastatic (NCCN)
	Note: NCCN recommended for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic).

Clinical Trials

View Clinical Trials for Malignant Salivary Gland Neoplasm

There are 6 clinical trials for malignant salivary gland neoplasm, of which 6 are open and 0 are completed or closed. Of the trials that contain malignant salivary gland neoplasm as an inclusion criterion, 6 are phase 2 (6 open).

ERBB2, HER2, and ABL1 are the most frequent gene inclusion criteria for malignant salivary gland neoplasm clinical trials [3].

Trials Investigating Malignant Salivary Gland Neoplasm by Gene and Recruiting Status

Nivolumab, trastuzumab, and nanoparticle-based paclitaxel suspension are the most common interventions in malignant salivary gland neoplasm clinical trials.

Drugs Being Investigated in Malignant Salivary Gland Neoplasm Trials by Recruiting Status

Significant Genes in Malignant Salivary Gland Neoplasm

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK +

ALK is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is an inclusion eligibility criterion in 2 clinical trials for malignant salivary gland neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and malignant salivary gland neoplasm as inclusion criteria, 2 are phase 2 (2 open) [3].

DDR2 +

DDR2 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR +

EGFR is an inclusion eligibility criterion in 2 clinical trials for malignant salivary gland neoplasm, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and malignant salivary gland neoplasm as inclusion criteria, 2 are phase 2 (2 open) [3].

EPHA2 +

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is an inclusion eligibility criterion in 3 clinical trials for malignant salivary gland neoplasm, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant salivary gland neoplasm as inclusion criteria, 3 are phase 2 (3 open) [3].

Ado-trastuzumab emtansine, pertuzumab, and trastuzumab have evidence of efficacy in patients with ERBB2 mutation in malignant salivary gland neoplasm [3].

ERBB4 +

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 +

FLT1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 +

FLT4 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK +

FRK is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FRK status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR +

KDR is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK11 +

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE +

POLE is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PTCH1 +

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 +

RAF1 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

SMO +

SMO is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMO status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TEK +

TEK is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TRNAK2 +

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA +

VEGFA is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB +

VEGFB is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC +

VEGFC is an inclusion eligibility criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

Cancer of the Salivary Gland, Salivary Gland Cancer, Malignant Salivary Gland Tumor

Parent(s)

Salivary Gland Neoplasm

Children

Malignant Parotid Gland Neoplasm, Malignant Sublingual Gland Neoplasm, Salivary Gland Carcinoma, Salivary Gland Carcinosarcoma, and Malignant Submandibular Gland Neoplasm

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Malignant Salivary Gland Neoplasm

Back to Diseases List

Associated Genetic Biomarkers

Overview

Biomarker-Directed Therapies

Clinical Trials

Significant Genes in Malignant Salivary Gland Neoplasm

Disease Details

References

About

Molecular Medicine

Content Types